BLU 6348
Alternative Names: BLU-6348Latest Information Update: 25 Jun 2021
At a glance
- Originator Blueprint Medicines
- Developer Blueprint Medicines; Roche
- Class Antineoplastics; Small molecules
- Mechanism of Action Hematopoietic progenitor kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 10 Apr 2021 Preclinical trials in Cancer in USA (PO) before April 2021
- 10 Apr 2021 Interim pharmacodynamics data from a preclinical study in Cancer presented at the 112th Annual Meeting of the American Association for Cancer Research (AACR-2021)
- 11 Jan 2021 Blueprint Medicines amends collaboration and license agreement with Roche to focus on MAP4K1 and an additional target for the treatment of Cancer